U.S. markets closed
  • S&P 500

    4,088.85
    +80.84 (+2.02%)
     
  • Dow 30

    32,654.59
    +431.17 (+1.34%)
     
  • Nasdaq

    11,984.52
    +321.73 (+2.76%)
     
  • Russell 2000

    1,840.30
    +56.87 (+3.19%)
     
  • Crude Oil

    113.66
    -0.54 (-0.47%)
     
  • Gold

    1,813.60
    -0.40 (-0.02%)
     
  • Silver

    21.64
    +0.09 (+0.41%)
     
  • EUR/USD

    1.0552
    +0.0113 (+1.09%)
     
  • 10-Yr Bond

    2.9680
    +0.0910 (+3.16%)
     
  • GBP/USD

    1.2492
    +0.0168 (+1.37%)
     
  • USD/JPY

    129.3520
    +0.2990 (+0.23%)
     
  • BTC-USD

    30,531.94
    +459.05 (+1.53%)
     
  • CMC Crypto 200

    677.94
    +435.26 (+179.36%)
     
  • FTSE 100

    7,518.35
    +53.55 (+0.72%)
     
  • Nikkei 225

    26,659.75
    +112.70 (+0.42%)
     

Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has decided not to advance Zygel against developmental and epileptic encephalopathies (DEE).

  • The decision was in line with the feedback from the FDA, which indicated that the selection of a specific DEE syndrome would be required to support its clinical trials for a pediatric indication, the company said.

  • Instead, Zynerba now plans to move the investigational cannabidiol gel against Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q).

  • Related: Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children.

  • The data for Zygel from a pivotal Phase 3 trial in FXS is expected in H2 of 2023.

  • Meanwhile, CEO Armando Anido expects its INSPIRE trial for Zygel in 22q to generate topline data in mid-2022.

  • “Putting resources behind a second indication beyond FXS and completing the INSPIRE trial is consistent with our mission of being a leader in rare and near-rare neuropsychiatric disorders, including FXS, ASD, and 22q,” he added.

  • With cash and equivalents at $75.6 million as of September 30, 2021, Zynerba believes its funding would be sufficient until H2 2023.

  • Price Action: ZYNE shares closed at $2.95 on Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.